OverviewSuggest Edit

Clearside Biomedical is a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye. It provides a non-surgical application for dosing drugs to distinct eye tissues, such as retina, trabecular meshwork, and corneal stroma. The Сompany’s CLS1001 is under development for retinal applications through the delivery of therapeutics to the suprachoroidal space.

TypePublic
Founded2011
HQAlpharetta, GA, US
Websiteclearsidebio.com

Latest Updates

Employees (est.) (Dec 2019)33(-34%)
Revenue (FY, 2020)$7.9 M(+264%)
Share Price (Jun 2021)$3(-3%)
Cybersecurity ratingAMore

Key People/Management at Clearside Biomedical

Charles A. Deignan

Charles A. Deignan

Chief Financial Officer
Rafael V. Andino

Rafael V. Andino

Vice President, Engineering & Manufacturing
William D. Humphries

William D. Humphries

Chairperson, Executive Vice President of Ortho Dermatologic
Richard Croarkin

Richard Croarkin

Director
George Lasezkay

George Lasezkay

President and Chief Executive Officer, Director
Rick McElheny

Rick McElheny

Vice President, Business Development
Show more

Clearside Biomedical Office Locations

Clearside Biomedical has an office in Alpharetta
Alpharetta, GA, US (HQ)
900 North Point Pkwy
Show all (1)

Clearside Biomedical Financials and Metrics

Clearside Biomedical Revenue

Clearside Biomedical's revenue was reported to be $7.89 m in FY, 2020
USD

Revenue (Q1, 2021)

34.0k

Net income (Q1, 2021)

(7.4m)

EBIT (Q1, 2021)

(8.3m)

Market capitalization (11-Jun-2021)

173.3m

Closing stock price (11-Jun-2021)

3.0
Clearside Biomedical's current market capitalization is $173.3 m.
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

520.0k345.0k30.0k2.2m7.9m

Revenue growth, %

(34%)

General and administrative expense

6.6m6.3m9.7m14.7m16.8m10.8m

R&D expense

10.8m19.5m49.1m68.3m15.7m15.1m
Quarterly
USDQ2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

Revenue

5.0k5.0k5.0k130.0k155.0k45.0k45.0k141.0k4.1m354.0k34.0k

General and administrative expense

970.0k1.6m2.7m2.3m2.3m3.6m3.9m4.4m5.0m3.8m3.1m2.6m2.9m

R&D expense

4.2m3.7m7.6m11.5m16.1m17.3m20.1m11.0m658.0k2.7m3.8m3.3m5.5m

Operating expense total

5.2m5.3m10.3m13.8m18.3m20.9m24.0m15.4m5.7m6.5m6.9m5.9m8.4m
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

20.3m34.8m9.2m8.0m22.6m17.3m

Prepaid Expenses

159.0k396.0k1.4m2.0m1.1m722.0k

Current Assets

20.5m84.3m39.2m42.9m25.2m18.1m

PP&E

156.0k94.0k885.0k790.0k541.0k416.0k
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(17.6m)(25.9m)(59.0m)(82.8m)(30.8m)(18.2m)

Depreciation and Amortization

60.0k65.0k182.0k189.0k211.0k180.0k

Accounts Payable

632.0k1.4m4.7m(314.0k)(5.6m)(631.0k)

Cash From Operating Activities

(13.9m)(22.7m)(51.1m)(79.2m)(27.1m)(13.1m)
USDFY, 2015

Financial Leverage

-0.6 x
Show all financial metrics

Clearside Biomedical Cybersecurity Score

Cybersecurity ratingPremium dataset

A

96/100

SecurityScorecard logo

Clearside Biomedical Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Clearside Biomedical Online and Social Media Presence

Embed Graph

Clearside Biomedical News and Updates

Clearside Biomedical to Participate in Two Upcoming Investor Conferences in June 2021

ALPHARETTA, Ga., June 09, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that George Lasezkay, Pharm.…

Bausch Health And Clearside Biomedical Announce U.S. FDA Filing Acceptance For XIPERE™ (triamcinolone acetonide suprachoroidal injectable suspension)

PDUFA Action Date Is October 30, 2021 LAVAL, QC and ALPHARETTA, Ga., June 2, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and Bausch + Lomb, its leading global eye health business, along with Clearside Biomedical, Inc. (Nasdaq: CLSD) ("Clearside"), a...

Clearside Biomedical Announces Multiple Poster Presentations at the Association for Research in Vision and Ophthalmology 2021 Virtual Meeting

Presentations support proprietary suprachoroidal space delivery platform and programs Presentations support proprietary suprachoroidal space delivery platform and programs

Clearside Biomedical Announces Resubmission of New Drug Application for XIPERE™ for Treatment of Macular Edema Associated with Uveitis

ALPHARETTA, Ga., May 03, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today the resubmission of its New …

Clearside Biomedical to Present at the Needham Virtual Healthcare Conference and Wet AMD & DME Drug Development Summit

ALPHARETTA, Ga., April 05, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that Thomas A. Ciulla, M.D.…
Show more

Clearside Biomedical Blogs

BAUSCH HEALTH AND CLEARSIDE BIOMEDICAL ANNOUNCE U.S. FDA FILING ACCEPTANCE FOR XIPERE™ (TRIAMCINOLONE ACETONIDE SUPRACHOROIDAL INJECTABLE SUSPENSION)

PDUFA Action Date Is October 30, 2021 LAVAL, Quebec, and ALPHARETTA, Ga., June 02, 2021 (GLOBE NEWSWIRE) -- Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health”) and Bausch + Lomb, its leading global eye health business, along with Clearside Biomedical, Inc.

Clearside Biomedical Announces First Quarter 2021 Financial Results and Provides Corporate Update

- Recent New Drug Application Resubmission for XIPERE TM (triamcinolone acetonide suprachoroidal injectable suspension) - - Cohort 1 Data in OASIS Wet AMD Phase 1/2a Trial Expected in June 2021 - - Multiple ARVO Presentations Highlight Suprachoroidal Delivery with SCS Microinjector ® - - Management

Clearside Biomedical to Report First Quarter 2021 Financial Results and Provide Corporate Update on Monday, May 17, 2021

Clearside Biomedical to Report First Quarter 2021 Financial Results and Provide Corporate Update on Monday, May 17, 2021 Content Import Tue, 05/04/2021 - 07:05 Clearside Biomedical to Report First Quarter 2021 Financial Results and Provide Corporate Update on Monday, May 17, 2021 …

Clearside Biomedical Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

- OASIS Wet AMD Phase 1/2a Trial Initiated and Cohort 1 Dosing Completed - - Initial Safety Data from OASIS Trial Expected Mid-2021 - - Four Ongoing Internal & Partner Clinical Trials Using Clearside’s SCS Microinjector ® - - Management to Host Webcast and Conference Call Today at 4:30 P.M.

Clearside Biomedical Announces Third Quarter 2020 Financial Results and Provides Corporate Update

Clearside Biomedical Announces Third Quarter 2020 Financial Results and Provides Corporate Update Content Import Tue, 11/10/2020 - 16:05 Clearside Biomedical Announces Third Quarter 2020 Financial Results and Provides Corporate Update 11/10/20 This release is…

Clearside Biomedical Frequently Asked Questions

  • When was Clearside Biomedical founded?

    Clearside Biomedical was founded in 2011.

  • Who are Clearside Biomedical key executives?

    Clearside Biomedical's key executives are Charles A. Deignan, Rafael V. Andino and William D. Humphries.

  • How many employees does Clearside Biomedical have?

    Clearside Biomedical has 33 employees.

  • What is Clearside Biomedical revenue?

    Latest Clearside Biomedical annual revenue is $7.9 m.

  • What is Clearside Biomedical revenue per employee?

    Latest Clearside Biomedical revenue per employee is $239.2 k.

  • Who are Clearside Biomedical competitors?

    Competitors of Clearside Biomedical include Alembic Pharmaceuticals, Biocon and Livzon Pharmaceutical Group.

  • Where is Clearside Biomedical headquarters?

    Clearside Biomedical headquarters is located at 900 North Point Pkwy, Alpharetta.

  • Where are Clearside Biomedical offices?

    Clearside Biomedical has an office in Alpharetta.

  • How many offices does Clearside Biomedical have?

    Clearside Biomedical has 1 office.